Premium
[P2–311]: CORTICAL BLINDNESS AND ANTON SYNDROME IN POSTERIOR CORTICAL ATROPHY
Author(s) -
Wu ChuangKuo
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.965
Subject(s) - posterior cortical atrophy , cortical blindness , atrophy , dementia , medicine , dementia with lewy bodies , psychology , pathology , disease , blindness , optometry
with reduced incidence of AD and improved cognitive function frommid-life to late-life, but intervention studies of up to five years in duration have not supported these findings (McGuinness B et al, 2016). Few studies have examined statin use over the long-term, and large systematic reviews have recommended long-term observational studies to elucidate these conflicting associations (Stephenson NE et al, 2016). Whilst up to two-thirds of people with dementia are women, even fewer studies have examined statin use in women. This study examined statin use and cognitive function in healthy Australian women. Methods: 175 Australian women (average age 1⁄4 69.70) from the Women’s Healthy Ageing Project, a prospective, long-term epidemiological study, were included in this analysis. Cognitive function was assessed using the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) word list. In accordance with National Institute on Ageing Alzheimer’s Association criteria, mild cognitive impairment was defined as 1.5 standard deviations below mean cognitive test performance (Albert MS et al, 2011). Statin use was self-reported by participants for the two decades prior to cognitive testing, which trained field researchers checked against a medication list. Results: Statins were used by the cohort for an average of 8.35 years. Of women who had taken statins, fewer than expected (4.41%) were in the low performing group of CERAD delayed recall. Conversely, more women who had never taken statins (15.89%) were in the low performing group. After adjustment for age, education level, body mass index, and PROCAM 10-year cardiovascular risk as confounding variables, users of statins at any time over the past twenty years were less likely to be in the low performing group for CERAD delayed recall (p<0.05). Conclusions: We observed that statin use by women at any time over the past twenty years was associated with improved CERAD delayed recall, and a reduced likelihood of mild cognitive impairment. Given potential implications of these findings, women need better representation in future studies examining cognition.